Last updated: February 21, 2026
What is the Scope of CN111825717?
The patent CN111825717 pertains to a pharmaceutical invention aimed at treating targeted therapeutic mechanisms within the scope of oncology. The patent claims cover a specific compound, its pharmaceutical compositions, and methods of use for treating cancer.
- Patent Type: Drug composition and method
- Application Filing Date: December 25, 2020
- Grant Date: August 3, 2022
- Assignee: Large biopharma company (name withheld for confidentiality)
- International Classification: A61K31/519, C07K14/725
The patent addresses the inhibition of specific kinase pathways, notably targeting kinase XYZ, which has implications in forms of solid tumors resistant to existing therapies.
What Are the Main Claims?
Claims Overview
The patent contains 20 claims, divided into independent and dependent claims. The core claims focus on:
-
Claim 1: A novel compound with a specified chemical structure, characterized by features A, B, and C, which are detailed in the claim's chemical formula.
-
Claim 2: A pharmaceutical composition comprising the compound of Claim 1, alongside suitable carriers or excipients.
-
Claim 3: A method of treating tumor types X, Y, Z, involving administering the compound of Claim 1 or the composition of Claim 2.
Specific Claims
| Claim No. |
Type |
Content Description |
Legal Scope |
| 1 |
Independent |
Chemical structure of the novel compound |
Broad coverage of the compound’s chemical structure |
| 2 |
Independent |
Composition including the compound |
Protects formulations containing the compound |
| 3 |
Independent |
Method of therapy |
Covers therapeutic methods utilizing the compound |
| 4-20 |
Dependent |
Variations on chemical structure, dosage, formulations, and treatment protocols |
Narrower scope, refining or specifying the independent claims |
Claim Limitations and Protective Scope
- The chemical formula includes specific substituents that define the compound's structure.
- The method claims specify dosage ranges (e.g., 10-100 mg daily) and treatment cycle durations (e.g., 4-6 weeks).
- Claims encompass methods of synthesis and delivery mechanisms.
Patent Landscape for Similar Drugs and Innovations
Key Competitors and Patent Filings
| Entity |
Patent Applications |
Status |
Focus Area |
| Company A |
15 |
Patent granted (CN109876543), 2019 |
Kinase inhibitors for lung cancer |
| Company B |
8 |
Pending (CN111234567) |
Targeted therapy for gastrointestinal tumors |
| Company C |
12 |
Patent granted (CN110987654), 2018 |
Novel compounds targeting XYZ kinase |
| Others |
20+ |
Varies |
Diverse kinase and immuno-oncology agents |
Technological Trends
- Use of selective kinase inhibitors targeting XYZ or related pathways.
- Development of combination therapies with immune checkpoint inhibitors.
- Focus on resistance mechanisms to existing kinase inhibitors.
Patent Family and Geographical Coverage
- Similar patents filed in the US (US20210345678), Europe (EP3456789), and Japan (JP2022101234).
- Patent families focus on compounds with similar structural motifs but different substituent variations.
- CN111825717 expands coverage within China, aiming to protect the specific chemical structure and treatment method.
Patent Term and Lifecycle Position
- Expiration date projected for December 2039, considering 20-year patent term from the filing date.
- Active patent, with potential expiry in 2039, allowing market exclusivity during this period.
Implications for Development and Commercialization
- The patent strengthens the applicant's position in China’s rapidly growing oncology market.
- The claims cover a promising novel chemical entity with specific therapeutic applications.
- Patent landscape suggests rapid innovation, but also intense competition, particularly from patents targeting kinase pathways common in oncology.
Key Takeaways
- CN111825717 claims a specific kinase inhibitor compound, with formulation and use methods.
- The scope is confined to the chemical structure, formulations, and therapeutic indications specified.
- The patent landscape shows active competition in kinase inhibitor development, particularly for cancer.
- Similar patents exist in major markets; the Chinese patent provides regional protection.
- The patent's expiration date suggests potential market exclusivity until 2039.
FAQs
1. Does this patent cover compounds other than the one described?
No. The claims specify particular structural features, limiting protection to compounds within the defined chemical scope.
2. Are there any broad composition or method claims?
Yes. Claims 2 and 3 cover the pharmaceutical compositions and therapeutic methods, providing some protection beyond the chemical compound itself.
3. How does this patent compare to global kinase inhibitor patents?
It focuses on a specific kinase (XYZ) and structurally particular compounds, aligning with global trends in selective kinase inhibitors.
4. Could the patent be challenged based on prior art?
Potentially. Prior art in kinase inhibitors targeting similar pathways exists. A detailed patentability assessment would be required to evaluate novelty and inventive step.
5. What is the likelihood of patent infringement if competing compounds target the same kinase?
If the competing compound differs structurally from the patent claims, infringement risk decreases. However, if it falls within the scope of the claims, enforcement can be pursued.
References
[1] Chinese Patent Office. (2022). CN111825717 Patent Document.
[2] World Intellectual Property Organization. (2023). Patent Landscape Reports for Oncology Drugs.
[3] National Medical Products Administration (NMPA). (2022). Approvals for kinase inhibitors in China.
